炎症性肠病临床决策支持工具的校准、临床效用与特异性
研究纳入280例克罗恩病(CD)和218例溃疡性结肠炎(UC)患者启动维得利珠单抗(VDZ),以及194例CD患者启动乌司奴单抗(UST),评估临床决策支持工具(CDST)的区分度、校准、临床效用与特异性。VDZ-CDST分组在临床和内镜缓解率上差异显著,UST-CDST仅对临床缓解有显著区分;VDZ-CDST高估临床缓解率,但更准确预测无需手术或剂量升级的VDZ持续治疗;与经验性治疗所有患者相比,VDZ-CDST在筛选持续治疗患者方面净获益更高;UST-CDST与VDZ-CDST预测应答的一致性为73.7%。
要点
- VDZ-CDST分组在临床和内镜应答及缓解率上差异显著,UST-CDST仅对临床缓解有显著区分。
- VDZ-CDST高估临床缓解率,但更准确预测无需手术或剂量升级的VDZ持续治疗。
- 与经验性治疗所有患者相比,VDZ-CDST在筛选持续VDZ治疗患者方面净获益更高。
核心结论
- VDZ-CDST能显著区分VDZ应答,且与经验性治疗所有患者相比,在识别无需手术或剂量升级而持续治疗的患者方面更有益。
研究设计与样本
- 纳入280例CD和218例UC患者启动VDZ,以及194例CD患者启动UST,评估CDST的区分度、校准、临床效用与特异性。
主要发现
- CDST将7.2%、50.0%、42.8%的患者分别分配至低、中、高应答概率组。
- VDZ-CDST分组在临床和内镜应答及缓解率上差异显著,UST-CDST分组仅对临床缓解显示显著区分。
- VDZ-CDST高估临床缓解率,但更准确预测无需手术或剂量升级的VDZ持续治疗率。
- 与经验性治疗所有患者相比,VDZ-CDST在筛选无需手术或剂量升级而持续VDZ治疗的患者方面净获益更高。
- UST-CDST与VDZ-CDST预测应答的一致性为73.7%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Clinical decision support tools (CDSTs) have been developed to predict response to vedolizumab (VDZ) and ustekinumab (UST) in Crohn's disease (CD) and ulcerative colitis (UC). In addition to assessing their discrimination performance, our study aimed to evaluate their calibration, clinical utility, and specificity. METHODS: We included 280 patients with CD and 218 patients with UC initiating VDZ, and 194 patients with CD initiating UST. We assessed discrimination by comparing rates of effectiveness outcomes between response probability groups forecasted by CDSTs. Calibration curves and decision curve analysis evaluated the calibration and clinical utility of VDZ-CDSTs. Additionally, we examined the agreement between UST-CDST and VDZ-CDST in assigning response probability groups among patients with CD starting UST. RESULTS: In the overall cohort, CDSTs allocated 7.2%, 50.0%, and 42.8% of the patients to the low-, intermediate-, and high-response probability groups, respectively. VDZ-CDSTs groups demonstrated significant differences in the rates of clinical and endoscopic response and remission, whereas UST-CDST groups showed significant discrimination only for clinical remission. Although VDZ-CDSTs overestimated clinical remission rates, they more accurately predicted rates of VDZ persistence without need for surgery or dose escalation. Compared with empirically treating all patients with VDZ, VDZ-CDSTs yielded higher net benefits in selecting patients who would continue VDZ without need for surgery or dose escalation. Finally, the agreement between UST-CDST and VDZ-CDST in predicting response was 73.7%. CONCLUSION: VDZ-CDSTs significantly discriminated response to VDZ and were more beneficial in identifying patients who would continue therapy without requiring surgery or dose escalation, compared with treating all patients empirically.
引用
- Alsoud D, Sabino J, Ferrante M, et al. Calibration, Clinical Utility, and Specificity of Clinical Decision Support Tools in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2024. PMID: 39461468. doi:10.1016/j.cgh.2024.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。